Jump to ContentJump to Main Navigation
Show Summary Details
More options …

European Journal of Nanomedicine

Editor-in-Chief: Hunziker, Patrick / Mollenhauer, Jan

Managing Editor: Löffler, Beat / Salieb-Beugelaar, Georgette

Editorial Board Member: Alexiou, Christoph / Balogh, Lajos / Barenholz, Yechezkel / Dawson, Kenneth / Fadeel, Bengt / Husseini, Ghaleb / Krol, Silke / Lee, Dong Soo / Lehr, Claus-Michael / Mangge, Harald / Müller, Bert / Peer, Dan / Scoles, Giacinto / Serruys, Patrick / Schwartz, Simo / Szebeni, Janos

4 Issues per year


CiteScore 2016: 1.06

SCImago Journal Rank (SJR) 2016: 0.411
Source Normalized Impact per Paper (SNIP) 2016: 0.360

Online
ISSN
1662-596X
See all formats and pricing
More options …

Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions

János Szebeni
  • Nanomedicine Research and Education Center, Semmelweis University and Bay Zoltán Applied Research Nonprofit Ltd., Budapest, Hungary
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar

Abstract

Infusion, or hypersensitivity reactions (HSRs) are frequent side effects of i.v. administered nanomedicines and biologicals. These, mostly mild and well tolerated, but occasionally severe or fatal allergic reactions represent a hemo-incompatibility due to activation of the complement (C) system. This review details the HSRs caused by marketed nanomedicines (liposomal drugs, micellar systems, polymer-conjugates of proteins, imaging agents, drug carrier nanosystems) and antibody therapeutics (mAbs), pointing out the remarkable similarity of clinical symptoms and difference from true (IgE-mediated) allergy. Beside the essentials, such as terminology, prevalence, risk factors and molecular and cellular mechanism of C activation-related pseudoallergy (CARPA) caused by the above agents, the paper highlights the biological rationale of these reactions, i.e., misinterpretation of nanoparticulate drugs by the immune system as pathogenic viruses, and C activation being an inherent function of mAbs. The public, as well as regulatory agencies are increasingly aware of the safety risks of possibly severe adverse immune reaction of drugs in the above categories, expressing need for new and appropriate immune toxicity tests in the preclinical stage. Here we outline and comment on the available methods for C activation and CARPA testing in vitro and in vivo, namely, the ELISA of C cleavage products (C3a, C5a, C4d, Bb, SC5b-9), the hemolytic (CH50) C assay, FACS measurement of basophil leukocyte activation, a – potentially – multiplex bead assay for C activation byproducts, the porcine assay of nanoparticle-induced cardiopulmonary distress and other CARPA tests in animals. The proven parallelisms between C activation and HSRs in vivo provide rationale for using these tests as predictors of infusion hypersensitivity, and the review suggests a decision tree for their use.

Keywords: adverse drug reactions; allergy; antibody; hypersensitivity; liposome; nanoparticles

About the article

Corresponding author: János Szebeni, MD, PhD, Dsc, Nanomedicine Research and Education Center, Semmelweis University, Budapest, 1089 Nagyvárad tér 4, Hungary


Published in Print: 2012-04-01


Citation Information: European Journal of Nanomedicine, ISSN (Online) 1662-596x, ISSN (Print) 1662-5986, DOI: https://doi.org/10.1515/ejnm-2012-0002.

Export Citation

©2012 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
János Szebeni, Zsóka Weiszhár, Zoltán Rozsnyay, Todd Martinsky, János Kádas, József Lázár, László Takács, and István Kurucz
Advances in Nanoparticles, 2013, Volume 02, Number 02, Page 133
[2]
Marziyeh Fathi, Parham Sahandi Zangabad, Ayuob Aghanejad, Jaleh Barar, Hamid Erfan-Niya, and Yadollah Omidi
Carbohydrate Polymers, 2017, Volume 172, Page 130
[3]
Roman Lehner, Kegang Liu, Xueya Wang, Marc Wolf, and Patrick Hunziker
Nanotechnology, 2017, Volume 28, Number 17, Page 175602
[4]
[5]
Anne Rix, Stanley Fokong, Sarah Heringer, Rastislav Pjontek, Lisa Kabelitz, Benjamin Theek, Marc-Alexander Brockmann, Martin Wiesmann, and Fabian Kiessling
Investigative Radiology, 2016, Volume 51, Number 12, Page 767
[6]
Valentina Agostoni, Soo Hyeon Lee, Vincent Forster, Meriam Kabbaj, Cristina R. Bosoi, Mélanie Tremblay, Matthias Zadory, Christopher F. Rose, and Jean-Christophe Leroux
Advanced Functional Materials, 2016, Volume 26, Number 46, Page 8382
[7]
Mohammad Akrami, Saeed Balalaie, Saman Hosseinkhani, Mohsen Alipour, Fahimeh Salehi, Abbas Bahador, and Ismaeil Haririan
Scientific Reports, 2016, Volume 6, Number 1
[8]
M. Elahi, Guoping Guan, Lu Wang, and Martin King
Materials, 2014, Volume 7, Number 4, Page 2956
[9]
Joshua A. Jackman, Tamás Mészáros, Tamás Fülöp, Rudolf Urbanics, Janos Szebeni, and Nam-Joon Cho
Nanomedicine: Nanotechnology, Biology and Medicine, 2016, Volume 12, Number 4, Page 933
[10]
Thaisa Baccarin, Montserrat Mitjans, Elenara Lemos-Senna, and Maria Pilar Vinardell
Toxicology in Vitro, 2015, Volume 30, Number 1, Page 421
[11]
Lucette Doessegger and Maria Longauer Banholzer
Clinical & Translational Immunology, 2015, Volume 4, Number 7, Page e39
[12]
Roman Lehner, Xueya Wang, Stephan Marsch, and Patrick Hunziker
Nanomedicine: Nanotechnology, Biology and Medicine, 2013, Volume 9, Number 6, Page 742
[13]
Kumiko Sakai-Kato, Nobuhiro Nishiyama, Masato Kozaki, Takeshi Nakanishi, Yoshihiro Matsuda, Mai Hirano, Hiroyuki Hanada, Shigeru Hisada, Hiroshi Onodera, Hideyoshi Harashima, Yasuhiro Matsumura, Kazunori Kataoka, Yukihiro Goda, Haruhiro Okuda, and Toru Kawanishi
Journal of Controlled Release, 2015, Volume 210, Page 76
[14]
Alain Beck, Paul J. Carter, Hans-Peter Gerber, Alexey A. Lugovskoy, Thierry Wurch, Jagath R. Junutula, Roland E Kontermann, and Robert Mabry
mAbs, 2013, Volume 5, Number 3, Page 339
[15]
[16]
Jolanda M. van den Hoven, Reka Nemes, Josbert M. Metselaar, Bastiaan Nuijen, Jos H. Beijnen, Gert Storm, and Janos Szebeni
European Journal of Pharmaceutical Sciences, 2013, Volume 49, Number 2, Page 265

Comments (0)

Please log in or register to comment.
Log in